Safety evaluation of the atmospheric low-temperature plasma (ALTP) on the conjunctiva: an animal study and histopathological findings; 6-month follow-up.
Atmospheric-pressure low-temperature plasma
Conjunctival tissue
Soft surgery
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
13 Sep 2021
13 Sep 2021
Historique:
received:
28
02
2021
accepted:
17
07
2021
entrez:
14
9
2021
pubmed:
15
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Plasma medicine is an innovative research field focused on the application of atmospheric-pressure low-temperature plasmas (ALTP) for therapeutic purposes. Considering the potentials of plasma in ophthalmology, in this study, we evaluated the safety of plasma on the conjunctival tissue in animal models for 6 months. Twelve adult male New Zealand albino rabbits were divided into four groups. The right eye of each rabbit was chosen for the test and the left eye was considered as the control. Experiments were performed using the Plexr device (GMV, Rocca Priora, RM, Italy). Four plasma spots were applied on the superior part of the conjunctiva (from 10 to 2 o'clock positions) using the continuous mode and a low power level (white handpiece) of the Plexr. For evaluation of the plasma safety, the histopathological changes were assessed 1 week (A), 1 month (B), 3 months (C), and 6 months (D) after the intervention. According to the histopathological findings, a mild decrease in blood vessels and severe stromal edema, as well as a superficial epithelium loss, were observed in group A. No chronic inflammation, scar tissue, deposition, and hemorrhage were found in group B. Epithelialization was confirmed by the histological examinations after 1 month. There was no evidence of atypia or dysplasia after 3 and 6 months. In conclusion, there were no persistent histopathological changes on conjunctival tissue after plasma exposure. Then, plasma can be considered as a minimally invasive alternative method for treating some ocular surface disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Plasma medicine is an innovative research field focused on the application of atmospheric-pressure low-temperature plasmas (ALTP) for therapeutic purposes. Considering the potentials of plasma in ophthalmology, in this study, we evaluated the safety of plasma on the conjunctival tissue in animal models for 6 months.
METHODS
METHODS
Twelve adult male New Zealand albino rabbits were divided into four groups. The right eye of each rabbit was chosen for the test and the left eye was considered as the control. Experiments were performed using the Plexr device (GMV, Rocca Priora, RM, Italy). Four plasma spots were applied on the superior part of the conjunctiva (from 10 to 2 o'clock positions) using the continuous mode and a low power level (white handpiece) of the Plexr. For evaluation of the plasma safety, the histopathological changes were assessed 1 week (A), 1 month (B), 3 months (C), and 6 months (D) after the intervention.
RESULTS
RESULTS
According to the histopathological findings, a mild decrease in blood vessels and severe stromal edema, as well as a superficial epithelium loss, were observed in group A. No chronic inflammation, scar tissue, deposition, and hemorrhage were found in group B. Epithelialization was confirmed by the histological examinations after 1 month. There was no evidence of atypia or dysplasia after 3 and 6 months.
CONCLUSION
CONCLUSIONS
In conclusion, there were no persistent histopathological changes on conjunctival tissue after plasma exposure. Then, plasma can be considered as a minimally invasive alternative method for treating some ocular surface disorders.
Identifiants
pubmed: 34517866
doi: 10.1186/s12886-021-02053-8
pii: 10.1186/s12886-021-02053-8
pmc: PMC8439071
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333Informations de copyright
© 2021. The Author(s).
Références
Dermatol Surg. 2018 Feb;44(2):283-290
pubmed: 28930794
Skin Res Technol. 2018 Aug;24(3):522-524
pubmed: 29405386
PLoS One. 2015 Jul 23;10(7):e0133173
pubmed: 26203910
J Cosmet Dermatol. 2020 Jan;19(1):55-60
pubmed: 31034761
Transl Vis Sci Technol. 2014 Mar 27;3(2):2
pubmed: 24757592
Am J Ophthalmol. 2018 Jun;190:150-163
pubmed: 29580975
Dermatol Surg. 2018 Dec;44(12):1509-1515
pubmed: 30020099
Clin Ophthalmol. 2020 Aug 26;14:2525-2532
pubmed: 32943834
Adv Ther. 2016 Jun;33(6):894-909
pubmed: 27142848
PLoS One. 2012;7(3):e33245
pubmed: 22432007
Acta Dermatovenerol Alp Pannonica Adriat. 2020 Jun;29(2):55-57
pubmed: 32566950
Exp Ther Med. 2020 Jan;19(1):717-721
pubmed: 31885709